Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Châtillon, France, June 29, 2026 DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review ...

Châtillon, France, July 16, 2026 DBV Technologies Announces the Filing of its 2026 Half-Year Report - Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV - ISIN: ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that it has filed a new automatically ...

DBV Technologies is presenting new positive Phase 3 data for its VIASKIN Peanut Patch, including results in children with additional atopic conditions. The company has also started a Phase 2 trial in ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today provided an update on the Biologics License Application (BLA) ...

Key Points Interested in DBV Technologies S.A.? Here are five stocks we like better. DBV Technologies is preparing to file a BLA for its VIASKIN Peanut Patch in Q3 2026 and said it may request ...

DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing ...

DBV to pursue an Accelerated Approval pathway for toddlers ages 1 - 3 years-old BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other ...